MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
0.6229
-0.0372
-5.64%
Opening 13:58 11/13 EST
OPEN
--
PREV CLOSE
0.6601
HIGH
0.6701
LOW
0.6100
VOLUME
76.03K
TURNOVER
--
52 WEEK HIGH
28.08
52 WEEK LOW
0.6100
MARKET CAP
1.13M
P/E (TTM)
-0.0107
1D
5D
1M
3M
1Y
5Y
1D
Aptevo Therapeutics Announces Warrant Exercise Financing Agreement
TipRanks · 19h ago
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
Barchart · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 2d ago
Aptevo Therapeutics announces exercise of existing warrants for $3M gross proceeds
Seeking Alpha · 2d ago
Aptevo Therapeutics announces exercise of warrants for $3M gross proceeds
TipRanks · 2d ago
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
Barchart · 2d ago
Aptevo Presents New Multispecific Immunotherapy Data at SITC 2026
TipRanks · 4d ago
Aptevo presents preclinical data at SITC 2026 on APVO451, APVO452
TipRanks · 4d ago
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.